<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

SU-DHL-6

Description

SU-DHL-6 (Lymphoma CDX Model) 

The SU-DHL-6 cell line was derived from a diffuse large B-cell lymphoma (DLBCL). It represents aggressive B-cell malignancies. SU-DHL-6 is commonly used in hematology research and therapeutic testing. Its consistent biology supports translational lymphoma studies. 

Key Features: 

  • Derived from diffuse large B-cell lymphoma. 
  • Aggressive B-cell lymphoma line. 
  • Suspension culture growth. 
  • Tumorigenic in xenografts. 

Applications: 
SU-DHL-6 supports evaluation of targeted therapies for DLBCL. It is used in biomarker development and signaling pathway studies. Researchers employ it in resistance and drug screening research. Its reproducibility makes it valuable for translational pipelines.

Details
Tumor Type
Lymphoma
Tumor Subtype
DLBCL (GCB)
Organism
Human
Mouse Sex
Female
Mouse Strain
NOD/SCID
Mutated Genes
ARID1A
Mutation: p.Q200Ter
Effect: Stop-Gain
EZH2
Mutation: p.Y646N
Effect: Missense Variant
Impact: Likely Pathogenic
TP53
Mutation: p.Y234C
Effect: Missense Variant
Impact: Pathogenic / Likely Pathogenic & Likely Pathogenic
Effect: Splice Acceptor Variant
Impact: Pathogenic & Likely Pathogenic & Not Provided
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin